Associate Professor, Pathology (Clinical), Stony Brook University SOM
Pathology
Dr. Dennis K. Galanakis, MD
|
|
Give Review
Doctor Dennis K. Galanakis, MD practices Pathology. He went to University of Saskatchewan College of Medicine. Dennis Galanakis is a published physician. He published 54 publications, including: 'Modulation of GABA(A) receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA).' Dennis Galanakis accepts Medicare payments and is registered with Medicare.gov.
Publications
- Soluble gC1qR Is an Autocrine Signal That Induces B1R Expression on Endothelial Cells.
- Control of Anti-Thrombogenic Properties: Surface-Induced Self-Assembly of Fibrinogen Fibers.
- Reduced platelet adhesion in flowing blood to fibrinogen by alterations in segment gamma316-322, part of the fibrin-specific region.
- Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time.
- Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions.
- Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
- Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
- Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects.
- Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
- Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage.
- To gel or not to gel.
- Thrombotic thrombocytopenic purpura and its look-alikes: A single institution experience.
- Fib420, the novel fibrinogen subclass: newborn levels are higher than adult.
- Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibr...
- Unusual A alpha 16Arg-->Cys dysfibrinogenaemic family: absence of normal A alpha-chains in fibrinogen from two of four heterozygous siblings.
- Platelet adhesion to late fibrinogen degradation products.
- Fibrinogen Stony Brook II: partial characterization of a heterozygously transmitted peptide A anomaly.
- Antifibrinogen IgG, fibrinogen, and Clq complexes circulating in a hypodysfibrinogenemic proband. Isolation, stoichiometry, and partial characterization.
- Evaluation of fibrinogen self-assembly: role of its αC region.
- Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications.
- Human fibrinogen heterogeneities: determination of the major Aalpha chain derivatives in blood.
- Evaluation of the role of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen.
- Cryoprecipitation of fibrin-fibrinogen complexes induced by the cold-insoluble globulin of plasma.
- The synthetic RGDS peptide inhibits the binding of fibrinogen lacking intact alpha chain carboxyterminal sequences to human blood platelets.
- Transient intermediates in the thrombin activation of fibrinogen. Evidence for only the desAA species.
- A functional assay suggests that heterodimers exist in two C-terminal gamma-chain dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV.
- Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications.
- Fibrinogen anomalies and disease. A clinical update.
- A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.
- Inherited dysfibrinogenemia: emerging abnormal structure associations with pathologic and nonpathologic dysfunctions.
- Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fib...
- The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.
- Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
- Evaluation of two new assays for determination of serum fibrinogen/fibrin degradation products.
- Circulating thrombin time anticoagulant in a procainamide-induced syndrome.
- The dimeric Aalpha chain composition of dysfibrinogenemic molecules with mutations at Aalpha 16.
- Monoclonal IgG anticoagulants delaying fibrin aggregation in two patients with systemic lupus erythematosus (SLE).
- Mutations on fibrinogen (gamma 316-322) are associated with reduction in platelet adhesion under flow conditions.
- Autologous whole plasma fibrin gel. Intraoperative procurement.
- Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of alphav/beta3 mRNA by fibrin1.
- Gangrene of the back, buttocks, fingers, and toes caused by transient cold agglutinemia induced by a cooling blanket in a patient with sepsis.
- Dysfibrinogenemia. A current perspective.
- Plasma cryoprecipitation studies: major increase in fibrinogen yield by albumin enrichment of plasma.
- Terminology for macromolecular plasmic derivatives of crosslinked fibrin.
- Binding of fibrinogen to ADP-treated platelets. Comparison of plasma fibrinogen fractions and early plasmic fibrinogen derivatives.
- Cigarette smoke contains anticoagulants against fibrin aggregation and factor XIIIa in plasma.
- The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis.
- Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates.
- Comparison of human plasma fibrinogen subfractions and early plasmic fibrinogen derivatives.
- Albumin modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen.
- Case report: treatment of an intracranial arteriovenous malformation in a patient with complicated hemophilia.
- Modulation of GABA(A) receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA).
- Thrombosis-associated antifibrinogen IgG1 κ impairs fibrin polymerization and enhances platelet activation.
Doctors Specialties
- Clinical Pathology
- Pathology
Accepted Insurances
Education
-
SUNY Health Science Center at Brooklyn -
Maimonides Medical Center -
University of Saskatchewan College of Medicine
Hospital
-
Stony Brook University Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811933492 |
| Last Name Of The Provider | GALANAKIS |
| First Name Of The Provider | DENNIS |
| View All |
Similar Doctors
|
|
Dr. Dhanalakshmi Balakrishnan, MD |
|
|
Dr. Eric D. Spitzer, MD |
|
|
Dr. Kenneth R. Shroyer, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joel H. Saltz, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jingxuan Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bernard P. Lane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay L. Bock, MD
This Doctor is OpenDoctor Recommended.
|